8-K: Xilio Therapeutics Announces Positive Pipeline Updates and First Quarter 2024 Financial Results

Xilio Therapeutics reported its first quarter 2024 financial results, highlighted by pipeline advancements and strategic collaborations.

Summary

• Xilio Therapeutics announced its first quarter 2024 financial results, along with updates on its pipeline and business strategy.
• The company plans to initiate a Phase 2 trial for XTX101 in combination with atezolizumab for microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024.
• Clinical data for XTX101 and XTX301 is expected to be reported in the fourth quarter of 2024.
• Xilio is advancing its research-stage pipeline of tumor-activated bispecifics and immune cell engagers.
• The company anticipates its current cash runway will extend into the second quarter of 2025.
• Xilio received $43.5 million in upfront payments from Gilead, including a $30 million cash payment and a $13.5 million equity investment.
• An additional $3.3 million was received from Gilead in April 2024 through a private placement.
• Xilio is eligible for up to $592.5 million in contingent payments and tiered royalties from Gilead.
• The company's cash and cash equivalents were $34 million as of March 31, 2024, compared to $44.7 million at the end of 2023.
• Xilio received approximately $44.6 million in gross proceeds in April 2024 from the Gilead deal and private placements.
• Research and development expenses were $10.4 million for the quarter, down from $16.1 million in the same period last year.
• General and administrative expenses decreased to $6.1 million from $7.4 million year-over-year.
• The net loss for the quarter was $17.2 million, compared to $22.6 million in the first quarter of 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant licensing deal with Gilead, the reduction in operating expenses, and the clear plan for advancing clinical programs. The company's financial outlook has improved, and there is a focus on innovation. However, the discontinuation of XTX202 as a monotherapy and the decrease in cash reserves temper the overall positive outlook.

Positives

• The company secured a significant licensing agreement with Gilead for its IL-12 program, providing substantial upfront funding and potential future milestones.
• Xilio has a clear plan to advance its clinical programs with defined timelines for trial initiations and data readouts.
• The company's cash position has been strengthened by the Gilead deal and private placements, extending the cash runway into Q2 2025.
• Xilio is actively developing a pipeline of tumor-activated bispecifics and immune cell engagers, indicating a focus on innovation.
• The company has reduced its operating expenses, including R&D and G&A, leading to a lower net loss compared to the same quarter last year.

Negatives

• The company's cash and cash equivalents decreased from $44.7 million at the end of 2023 to $34 million as of March 31, 2024.
• Xilio has discontinued further investment in XTX202 as a monotherapy, indicating a strategic shift in its portfolio.

Risks

• The company's success is dependent on the clinical trial results of its product candidates, which are subject to inherent risks and uncertainties.
• Xilio's ability to achieve future milestones and receive contingent payments from Gilead is not guaranteed.
• The company's financial performance is subject to market conditions and the success of its research and development efforts.
• There are risks associated with the development of novel therapies, including potential safety issues and regulatory hurdles.

Future Outlook

Xilio anticipates that its existing cash and cash equivalents, along with the upfront payment from Gilead and proceeds from private placements, will be sufficient to fund its operations into the second quarter of 2025. The company plans to advance its clinical programs for XTX101 and XTX301 and continue to develop its research-stage pipeline.

Management Comments

• In the first quarter, our team remained hard at work advancing our differentiated pipeline of clinical-stage tumor-activated I-O therapies, and we believe we are well-positioned to execute on several anticipated near-term clinical milestones and potential value-drivers in the coming year, said Ren Russo, Pharm.D., president and chief executive officer of Xilio.
• Looking ahead, we continue to focus on advancing the clinical development of XTX301, our tumor-activated IL-12, and XTX101, our tumor-activated, Fc-enhanced anti-CTLA-4, with clinical data from both programs expected later this year.

Industry Context

This announcement reflects the ongoing trend in the biotechnology industry towards developing targeted immuno-oncology therapies. The collaboration with Gilead highlights the value of Xilio's tumor-activated technology and its potential to address unmet needs in cancer treatment. The focus on bispecifics and immune cell engagers aligns with the industry's interest in next-generation immunotherapies.

Comparison to Industry Standards

• Xilio's collaboration with Gilead for its IL-12 program is comparable to other significant licensing deals in the immuno-oncology space, such as the collaboration between Nektar Therapeutics and Bristol-Myers Squibb for bempegaldesleukin.
• The planned Phase 2 trial for XTX101 in MSS CRC is similar to other trials evaluating anti-CTLA-4 therapies in combination with checkpoint inhibitors, such as the ongoing trials for ipilimumab and nivolumab.
• The focus on tumor-activated bispecifics and immune cell engagers is in line with the industry's move towards more targeted and effective immunotherapies, similar to the development of bispecific antibodies by companies like Regeneron and Amgen.
• The reported cash runway into Q2 2025 is a common metric for biotech companies, and Xilio's projection is in line with industry standards for companies at a similar stage of development.

Stakeholder Impact

• Shareholders will benefit from the increased cash runway and potential future revenue from the Gilead deal.
• Employees may be impacted by the strategic portfolio reprioritization and workforce reduction, but the company's focus on key programs may provide stability.
• Patients may benefit from the development of new cancer therapies with improved efficacy and reduced side effects.
• The collaboration with Gilead may lead to new opportunities for suppliers and partners.

Next Steps

• Initiate Phase 2 trial for XTX101 in combination with atezolizumab in MSS CRC in Q3 2024.
• Report clinical data for XTX101 and XTX301 in Q4 2024.
• Continue advancing the research-stage pipeline of tumor-activated bispecifics and immune cell engagers.
• Present data from the Phase 1/2 trial for XTX202 at the ASCO Annual Meeting from May 31 to June 4, 2024.

Key Dates

Keywords

immuno-oncology, tumor-activated, anti-CTLA-4, IL-12, bispecifics, clinical trials, biotechnology, Gilead, XTX101, XTX301, cancer therapy